MAPK1 and gastric cancer: For example, in gastric cancer, inhibition of the miR-665/MAPK1 signaling pathway not only reduces the expression of drug pumps, but also decreases the secretion of inflammatory factors like CD34 in the tumor microenvironment, thereby increasing the sensitivity of tumor cells to antitumor drugs [27,126].